アブストラクト
| Title | 進行肝細胞癌に対する薬物治療 ; 2次治療, 3次治療の薬剤選択 |
|---|---|
| Subtitle | 今月のテーマ (総説) : 肝細胞癌における薬物治療の進歩 |
| Authors | 小笠原定久1)2), 近藤孝行, 加藤直也1) |
| Authors (kana) | |
| Organization | 1)千葉大学大学院医学研究院消化器内科学, 2)千葉大学医学部附属病院臨床研究開発推進センター |
| Journal | 日本消化器病学会雑誌 |
| Volume | 118 |
| Number | 5 |
| Page | 418-427 |
| Year/Month | 2021 / 5 |
| Article | 報告 |
| Publisher | 日本消化器病学会 |
| Abstract | 要旨:進行肝細胞癌に対してアテゾリズマブ/ベバシズマブ併用療法が用いられるようになり, 薬物治療のランドスケープが大きく変わろうとしている. 今までのほぼすべての進行肝細胞癌の第III相試験は, ソラフェニブが進行肝細胞癌の1次治療であることを前提に試験がデザインされてきた. すなわち, アテゾリズマブ/ベバシズマブ併用療法後の後治療のエビデンスはほぼなく, 今後リアルワールドにて作り上げていくこととなる. アテゾリズマブ/ベバシズマブ併用療法が進行肝細胞癌治療の1次治療の主軸になる時代において, 2次治療以降を選択する際の一助となるべく, 治療選択肢となる薬剤の特徴と現在までに得られている知見について述べる. |
| Practice | 臨床医学：内科系 |
| Keywords | 肝細胞癌, 薬物治療, 2次治療, 3次治療 |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359;378-390:2008
- 2) Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10;25-34:2009
- 3) Cheng AL, Kang YK, Lin DY, et al: Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 31;4067-4075:2013
- 4) Johnson PJ, Qin S, Park JW, et al: Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31;3517-3524:2013
- 5) Cainap C, Qin S, Huang WT, et al: Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 33;172-179:2015
残りの42件を表示する
- 6) Zhu AX, Rosmorduc O, Evans TR, et al: SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hcpatocellular carcinoma. J Clin Oncol 33;559-566:2015
- 7) Llovet JM, Decaens T, Raoul JL, et al: Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31;3509-3516:2013
- 8) Kudo M, Moriguchi M, Numata K, et al: S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. Lancet Gastroenterol Hepatol 2;407-417:2017
- 9) Rimassa L, Assenat E, Peck-Radosavljevic M, et al: Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol 19;682-693:2018
- 10) Kudo M, Finn RS, Qin S, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391;1163-1173:2018
- 11) Bruix J, Qin S, Merle P, et al: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 triai. Lancet 389;56-66:2017
- 12) Abou-Alfa GK, Meyer T, Cheng AL, et al: Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 379;54-63:2018
- 13) Zhu AX, Kang YK, Yen CJ, et al: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20;282-296:2019
- 14) El-Khoueiry AB, Sangro B, Yau T, et al: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389;2492-2502:2017
- 15) Zhu AX, Finn RS, Edeline J, et al: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19;940-952:2018
- 16) Yau T, Park JW, Finn RS, et al: CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 30 (suppl 5):v874-v875:2019
- 17) Finn RS, Ryoo BY, Merle P, et al: Pembrolizumab As Second-Line Therapy in Patients With Advanccd Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 38;193-202:2020
- 18) Finn RS, Qin S, Ikeda M, et al: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382;1894-1905:2020
- 19) Llovet JM, Vilianueva A, Marrero JA, et al: Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 73 (suppl 1);158-191:2021
- 20) Gordan JD, Kennedy EB, Abou-Alfa GK, et al: Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol 38;4317-4345:2020
- 21) 肝癌診療マニュアル, 第4版, 医学書院. 2020
- 22) 肝癌診療ガイドライン 2017年版補訂版. Available at: http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/examination_jp_2017_Correct
- 23) Yoo C, Kim JH, Ryu MH, et al: Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study, Gastrointestinal Cancer Symposium (ASCO-GI), Abstract #272:2021
- 24) Ogasawara S, Kanai F, Obi S, et al: Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int 5;850-856:2011
- 25) Ogasawara S, Chiba T, Ooka Y, et al: Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 33;729-739:2015
- 26) Tovoli F, Ielasi L, Casadei-Gardini A, et al: Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol 71;1175-1183:2019
- 27) Reig M, Rimola J, Torres F, et al: Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 58;2023-2031:2013
- 28) Ogasawara S, Chiba T, Ooka Y, et al: Postprogression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. Invest New Drugs 34;255-260:2016
- 29) Koroki K, Kanogawa N, Maruta S, et al: Post-treatment after lenvatinib in patients with advanced hepatocellular carcinoma. Gastrointestinal Cancer Symposium (ASCO-GI), Abstract #278: 2021
- 30) Hiraoka A, Kumada T, Kariyama K, et al: Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med 8;137-146:2019
- 31) Maruta S, Ogasawara S, Ooka Y, et al: Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 9;382-396:2020
- 32) Aoki T, Kudo M, Ueshima K, et al: Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade. Cancers 12;3048:2020
- 33) Eso Y, Nakano S, Mishima M, et al: Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma. Cancers 12;49:2019
- 34) Kirino S, Tsuchiya K, Kurosaki M, et al: Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS One 15;e0231828:2020
- 35) Ogasawara S, Chiba T, Ooka Y, et al: Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Invest New Drugs 36;332-339:2018
- 36) Uchikawa S, Kawaoka T, Aikata H, et al: Clinical outcomcs of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. Hepatol Res 48;814-820:2018
- 37) Terashima T, Yamashita T, Sunagozaka H, et al: Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy. Hepatol Res 48;956-966:2018
- 38) Sonbol MB, Riaz IB, Naqvi SAA, et al: Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA Oncol 6;e204930:2020
- 39) Zhu AX, Park JO, Ryoo BY, et al: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 16;859-870:2015
- 40) Kudo M, Galle PR, Brandi G, et al: Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. JHEP Rep 3;100215:2020
- 41) Kudo M, Galle PR, Llovet JM, et al: Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int 40;2008-2020:2020
- 42) Kuzuya T, Ishigami M, Ito T, et al: Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma. Anticancer Res 40;2089-2093:2020
- 43) Finn RS, De Toni EN, Yau T, et al: Ramucirumab For Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following A Non-Sorafenib Based Systemic Therapy: Interim Results from An Expansion Cohort of The Phase 3 Reach-2 Study. International Liver Cancer Association 2020 conference, P-03:2020
- 44) Tabernero J, Yoshino T, Cohn AL, et al: Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16;499-508:2015
- 45) Lieu CH, Tran H, Jiang ZQ, et al: The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One 8;e77117:2013
- 46) Kudo M, Tsuchiya K, Kato N, et al: Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. J Gastroenterol 56;181-190:2021
- 47) Kebayashi K, Ogasawara S, Takahashi A, et al: Transition of molecular target agent therapy in advanced hepatocellular carcinoma: A multicenter, retrospective study. Gastrointestinal Cancer Symposium (ASCO-GI), Abstract #317:2021
